13 citations
,
September 2018 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
32 citations
,
April 2019 in “JAAD case reports” JAK inhibitors helped treat hair loss in two people with Down syndrome.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
June 2025 in “Journal of Education Health and Sport” Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
April 2026 in “International Journal of Drug Delivery Technology” Alopecia can often be managed effectively with various treatments, but early diagnosis is crucial for preventing permanent hair loss.
1 citations
,
October 2018 in “InTech eBooks” Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.
6 citations
,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
1 citations
,
February 2021 in “Farmacja Polska” Janus kinase inhibitors show promise in treating autoimmune skin diseases.
April 2024 in “Medical & clinical research” More research is needed to find the best long-term treatments for Alopecia Areata.
November 2023 in “Journal of Investigative Dermatology” JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.
September 2023 in “Frontiers in medicine” The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
11 citations
,
November 2018 in “Journal of the American Academy of Dermatology” Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.
July 2025 in “International Journal of Pharmaceutical Sciences Review and Research” Individualized treatment and psychological support improved the patient's quality of life and appearance despite medication side effects.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
16 citations
,
June 2017 in “Advances in Therapy” New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.
January 2026 in “Forum Dermatologicum” JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
October 2023 in “International journal of biology, pharmacy and allied sciences” Personalized treatment plans combining natural and synthetic approaches are important for managing alopecia effectively.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
February 2026 in “Colloids and Surfaces A Physicochemical and Engineering Aspects” JAK inhibitors can enter the skin through hair follicles using a unique pathway.